Cargando…

Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations

Unlike genomic alterations, gene expression profiles have not been widely used to refine cancer therapies. We analyzed transcriptional changes in acute myeloid leukemia (AML) cell lines in response to standard first-line AML drugs cytarabine and daunorubicin by means of RNA sequencing. Those changes...

Descripción completa

Detalles Bibliográficos
Autores principales:	More, Piyush, Ngaffo, Joëlle Aurelie Mekontso, Goedtel-Armbrust, Ute, Hähnel, Patricia S., Hartwig, Udo F., Kindler, Thomas, Wojnowski, Leszek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10455220/ https://www.ncbi.nlm.nih.gov/pubmed/37629110 http://dx.doi.org/10.3390/ijms241612926

Ejemplares similares

Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells
por: More, Piyush, et al.
Publicado: (2019)

Pregnane X Receptor and Yin Yang 1 Contribute to the Differential Tissue Expression and Induction of CYP3A5 and CYP3A4
por: Nem, Dieudonné, et al.
Publicado: (2012)

Structural and Functional Similarity of Amphibian Constitutive Androstane Receptor with Mammalian Pregnane X Receptor
por: Mathäs, Marianne, et al.
Publicado: (2014)

Correction: Structural and Functional Similarity of Amphibian Constitutive Androstane Receptor with Mammalian Pregnane X Receptor
por: Mathäs, Marianne, et al.
Publicado: (2016)

Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both Topoisomerase II isoforms
por: Deng, Shiwei, et al.
Publicado: (2014)

Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice
por: Deng, Shiwei, et al.
Publicado: (2009)

Alleviation of Postharvest Chilling Injury of Carambola Fruit by γ-aminobutyric Acid: Physiological, Biochemical, and Structural Characterization
por: Ngaffo Mekontso, Francine, et al.
Publicado: (2021)

TAF-ChIP: an ultra-low input approach for genome-wide chromatin immunoprecipitation assay
por: Akhtar, Junaid, et al.
Publicado: (2019)

Accuracy and Completeness of Drug Information in Wikipedia: A Comparison with Standard Textbooks of Pharmacology
por: Kräenbring, Jona, et al.
Publicado: (2014)

Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML
por: Volk, Andrew, et al.
Publicado: (2014)

PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML
por: Kelekci, Simge, et al.
Publicado: (2023)

Systemic Treatments for Mesothelioma: Standard and Novel
por: Kindler, Hedy Lee
Publicado: (2008)

Identification of a novel circularized transcript of the AML1 gene
por: Xu, Ai-ning, et al.
Publicado: (2013)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

Explainable AI identifies diagnostic cells of genetic AML subtypes
por: Hehr, Matthias, et al.
Publicado: (2023)

81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML
por: Jones, LaQuita, et al.
Publicado: (2021)

Synergistic inhibitory effects of low-dose decitabine in combination with bortezomib in the AML cell line Kasumi-1
por: Mpakou, Vassiliki, et al.
Publicado: (2021)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
por: Lambert, Juliette, et al.
Publicado: (2014)

Upfront Screening by Quantitative Real-Time PCR Assay Identifies NUP98::NSD1 Fusion Transcript in Indian AML Patients
por: Shah, Arunim, et al.
Publicado: (2022)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
por: Sollier, Etienne, et al.
Publicado: (2023)

YBX1 mediates translation of oncogenic transcripts to control cell competition in AML
por: Perner, Florian, et al.
Publicado: (2021)

Experimental Study on the Correlation between miRNA-373 and HIF-1α, MMP-9, and VEGF in the Development of HIE
por: Liu, Chun-Yang, et al.
Publicado: (2021)

Synergistic and antagonistic AML cell type-specific responses to 5-AZA-2’-Deoxycytidine and 1-H-D-Arabinofuranosylcytosine
por: Elmoneim, Abeer Abd, et al.
Publicado: (2014)

Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation
por: Tsitsipatis, Dimitrios, et al.
Publicado: (2017)

Instruction of haematopoietic lineage choices, evolution of transcriptional landscapes and cancer stem cell hierarchies derived from an AML1-ETO mouse model
por: Cabezas-Wallscheid, Nina, et al.
Publicado: (2013)

A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC
por: Brand, Jaap, et al.
Publicado: (2013)

Next Generation Sequencing in AML—On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation?
por: Leisch, Michael, et al.
Publicado: (2019)

P535: OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND
por: Nguyen, Daniel, et al.
Publicado: (2023)

Standardization of Molecular MRD Levels in AML Using an Integral Vector Bearing ABL and the Mutation of Interest
por: Nachmias, Boaz, et al.
Publicado: (2023)

Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles
por: Hatlen, Megan A., et al.
Publicado: (2016)

Development of an instructional movie illustrating a standardized clinical examination on patients with TMD symptoms
por: Rauch, Angelika, et al.
Publicado: (2020)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Essentiality of the Maltase AmlE in Maltose Utilization and Its Transcriptional Regulation by the Repressor AmlR in the Acarbose-Producing Bacterium Actinoplanes sp. SE50/110
por: Schaffert, Lena, et al.
Publicado: (2019)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2023)

Correction to: A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2022)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
por: Janssen, Jeroen, et al.
Publicado: (2021)

The methyltransferase G9a regulates HoxA9-dependent transcription in AML
por: Lehnertz, Bernhard, et al.
Publicado: (2014)

Prognostic Value of AML1/ETO Fusion Transcripts in Patients with Acute Myelogenous Leukemia
por: Cho, Eun Kyung, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_9eqij1qe4d4c4vja5v4mj0c209